Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 3/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17026525 | 0.79 | CA12 (0.49) | FGFR1FGFR2FGFR3METAP2HSP90AA1 | |
| SCHEMBL31436559 | 0.79 | CA12 (0.49) | FGFR1FGFR2FGFR3METAP2HSP90AA1 | |
| SCHEMBL20357863 | 0.74 | NPC1 (0.43) | MAPTMEN1KMT2AGAARAB9A | |
| SCHEMBL176760 | 0.74 | KDR (0.36) | FGFR1METAP2CDK2TRPA1 | |
| SCHEMBL2305707 | 0.74 | KDR (0.36) | FGFR1METAP2 | |
| SCHEMBL13923957 | 0.73 | FGFR1 (0.57) | FGFR1FGFR2FGFR3METAP2HSP90AA1 | |
| SCHEMBL176764 | 0.73 | TTK (0.37) | FGFR1MAPTKDM4EHTTRAB9A | |
| Hydrochloric Acid SCHEMBL29920009 | 0.73 | KDM4E (0.58) | FGFR1FGFR2FGFR3METAP2MAPT | |
| SCHEMBL29130012 | 0.72 | NOS1 (0.41) | FGFR1HSP90AA1IDO1CDK2MAPT | |
| SCHEMBL1908641 | 0.72 | AKT1 (0.39) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7994202-B2 | Bicyclic nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| EP-2351742-A1 | INDAZOLE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351742-A1 | INDAZOLE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| CN-102089302-A | Nitrogenated bicyclic heterocyclic compound | ASAHI KASEI PHARMA CORP | 2011-06-08 | — | — | CN | disclosed |
| EP-2298767-A1 | NITROGENATED BICYCLIC HETEROCYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| WO-2010041569-A1 | INDAZOLE COMPOUND | 旭化成ファーマ株式会社 (JP) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010041568-A1 | INDAZOLE DERIVATIVE | 旭化成ファーマ株式会社 (JP) | 2010-04-15 | — | — | WO | disclosed |
| US-20100029733-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | FGFR1 612/4885FGFR2 938/4885FGFR3 390/4885 |
| US-20100029733-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PTGER1, EDNRA, NMUR1 | FGFR1 1162/4885FGFR2 2652/4885FGFR3 812/4885 |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ADRB3, INSR, ADRB1 | FGFR1 148/4885FGFR2 262/4885FGFR3 78/4885 |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | FGFR1 385/4885FGFR2 624/4885FGFR3 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.